"there is an issue that needs to be addressed in terms of the narrative the health trust tried to present and mislead the inquest and cover up what actually happened..
..
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...
the total amount paid out in life claims was £129.4m, with £13.46m paid in terminal illness claims..